MARS SHOT TM Research
Audubon's MARS SHOT TM Research
Audubon Health Group companies are strengthening their cancer-fighting efforts by engaging in collaborative research focused on advancing the understanding of basic cancer biology and primary cancer mechanisms to foster the discovery of innovative and improved cancer diagnostics and treatments.
We highly admire governmental exploratory programs, but our team is especially inspired by the efforts of private companies to excel in the 21st century utilizing modern technologies combined with the efficient allocation of resources and start-up culture.
Thus we want to name our cancer research collaborations and initiatives the cancer Mars Shot TM research.
With these goals in mind, our team currently focuses on translational medicine and collaborative projects: making deeper contributions to the US National Cancer Institute CPTAC and other projects, joining the European Union HORIZON 2020 program TRANSCAN and applying for US NIH grants.
As we pursue meaningful growth and impactful results, we are accumulating the resources and expertise to begin our own research using cutting-edge technologies, including AI (Artificial Intelligence). To this end, we have the following 7 objectives we wish to outline:
Aim 1: Decipher the tumor microenvironment (TME) subclasses and their contribution to cancer resistance mechanisms
Our goal is to further understand the different players within the tumor microenvironment and develop minimal or non-invasive tools, allowing the prediction of treatment efficacy and tumor recurrence. Our efforts are focused on using a population-based approach for the validation of plasma cell-free DNA (cfDNA) as a potential quantitative and predictive cancer biomarker.
Aim 2: Target the TME to improve immunotherapy efficiency in cancer patients
To this end, we will use a population-based approach to analyze the changes in expression of PBMC-related immune biomarkers in cancer patients undergoing tumor immunotherapy. We expect to identify the expression dynamics of immune biomarkers throughout immunotherapy progression and establish a reliable and non-invasive prediction method of immunotherapy responsiveness.
Aim 3: Develop artificial intelligence (AI) models to predict targeted therapies and immunotherapy treatment outcomes
We believe that AI has a large potential to unleash targeted therapies and immunotherapy's dormant potential. Therefore, a part of our research strategy is focused on supporting the development of AI models, trained and validated on patient collected data and real-life scenarios and outcomes. Our ultimate goal is to deliver accurate and efficient personalized predictions of a patient's response to a certain immunotherapy.
Aim 4: Identify cancer-associated genetic variants in the Ukrainian and Turkish populations
Our goal is to create a genetic database of genetic variants associated with cancer predisposition in the Ukrainian and Turkish populations. To this end, we will collect and analyze single-nucleotide polymorphism (SNP) data from previous GenomeWide Association Studies (GWAS) and expression data (QTL database, GTEx database) to identify the most common genome alterations in cancer patients. As a second step, we plan to collect our proprietary SNP library from cancer blood samples to predict recurrence-free survival and appropriate treatment plans for cancer patients.
Aim 5: Identify somatic mutations in Ukrainian and Turkish cancer patients using Next Generation Sequencing (NGS) techniques
Acquired mutations, or somatic mutations, are the most common causes of cancer. Our goal is to identify somatic mutations specific to the Ukrainian and Turkish population and validate them as prognostic cancer biomarkers. By identifying such mutations and helping clinicians to progress towards targeted cancer therapy, we plan to develop new standards of care for cancer patients in Ukraine.
Aim 6: Educate patients and society about the importance of biobanks and how they support cutting-edge biomedical research
We understand the key role of biospecimens for the advancement of clinical research is often unclear and not well communicated to the larger public. We are fighting against this trend by raising awareness and educating society and patients of the importance of biospecimen donation.
Aim 7: Help developing countries build biobanking infrastructure and modern precision medicine research capabilities through legislation, experience, technology, and equipment
The Audubon Bioscience team contributes to improving biobanking infrastructure and modern precision medicine research capabilities in the countries where we operate. For now, these are Ukraine, Turkey, Romania, United States, Georgia, and Nigeria. These countries include many ethnic groups which are underrepresented in regular studies and often suffer from the lack of access to relevant cancer diagnostics and treatments. As such, we want to take a step towards improving cancer screening and treatment, especially in the case of the most effective modern cancer therapies, such as targeted therapy and immunotherapy.
We support this process by working on improving local legislations, distributing educational materials to medical staff and patients, providing training to doctors (especially pathologists), nurses and lab assistants, and by purchasing equipment (freezers and centrifuges) to ensure biosample research quality.